Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I do like slow and steady. On the other hand, if a blockbuster RNS appeared I would not complain!! 😂
Tell me about it, I had pound signs rolling around behind the eyes … Mortgage, check! Family holiday, check! Holiday home, check! … and then reality kicked in and back to the grindstone. C’est la vie !
Let’s see how things pan out today after a green finish yesterday.
- EP
To be fair … it took a lot of people by surprise particularly after the drop a few days earlier. Friday, prior to the halt, I think it was trading circa 9$ … so don’t be too hard on yourself! Hopefully the beginning of something epic. On another board, I was drawn to the attention of CASSAVA SCIENCES, which went from circa $2 to $100 in around 18 months. Not advocating that this will happen here, but made for fun daydreaming for 5 minutes!
GLA - EP
I kick myself for being too casual about the performance of this share, and gutted to have missed the opportunity to sell around 11 bucks! Not sure how I missed the dialogue here, around the month end, but only just spotted the rise on my actual share account. Even with the drop, I am still now in profit - the question is, are we on a roll? Off on hols to the US on Thursday so unlikely to be keeping this under close observation!! Actually I will be dialling in every night! GLA. This is long overdue a good result.
Mighty news.
Premarket looks good
Https://www.stocktitan.net/news/SMMT/summit-raises-200-million-also-expands-license-territories-for-zimcyqwkvoom.html
UPDATE - sorry for the monologue posting :)
- EP
Potentially bodes well for SMMT
Good luck today and in the coming days/weeks LTH’s
- EP
So I received a news release from Summit at 06.32 today (Saturday) - weird. More excitement anyway - this time about the Harmoni A trial, separate from the Harmoni-2 trial - I won't pretend to understand it in any kind of detail but the words 'Showed Clinically Meaningful and Statistically Significant Benefit' seem relevant :-). Monday morning /afternoon could be rather interesting.
Interesting turn of events: trading halt pending news. But not before some very chunk in-the-know trades might have gone in at the last minute. Many assuming the halt is because of the content in the press conference Monday.
Wait and see.
Have a good weekend
- EP
Agreed 100% hold for me now.
A year will tell the story now
Always hard to argue against taking a profit, but...remember Keytruda has sales of $25 billion a year. We don't have rights to all markets but if we really do outperform it, and that's what we're saying, then that's a mighty big market to chip away at. I think there's good reason to hold for sometime yet.
Looks like some big profit taken back yesterday after market and premarket this morning.
Probably end up in 4 and 3 dollars again when settled.
Hi EP - Great post & sums the situation up very well .I was not aware that my son had finally got his shares on a site & would have advised him to sell at its peak last night as the SP has now receded more than I had expected.Ian will now still be at a loss thanks to me so he will need to wait.I am expecting a further increase in the SP as more news comes out.
As a rule of thumb having once been invested I would Sell, if in profit, to recover my initial investment & then Hold.
I check every day the SMMT activity so will keep people posted.
Regards
CM
PS I am currently showing Hold
Morning all ... I nearly fell off my chair this morning. I thought Google Finance was registering an error ... fimrly back in the black and then some just now.
If any wise souls want to advise their thoughts for me or Chris's son as to where we "think" this could go (I use "" because who among us really know much of anything haha), I am all ears. Fridays are always fun ... I imagine it will go a little bananas and then a sell-off into the weekend. The question being however ... what legs and potential does this news bring?
Any and all response is much appreciated.
First mission for me: recover the initial investment at the most advantageous moment I am comfortable with and let the rest run ...
GLA - EP
ps. Thanks Chris for the well wishes. Good luck to your boy
Https://finance.yahoo.com/news/summit-shares-soar-lung-cancer-195343904.html
Brilliant news
The SP is still rising now at $11.60 I have reverted to Hold . Good luck my son is now in profit after many years.Good luck EP.
Hi All - Positive results on their cancer drug out the evening uk time.
PS: I am showing Strong Sell only to encourage people to get their money back but my son is still not in profit & will Hold.I hope that makes sense.
Investors reacted negatively to the late-stage data for ivonescimab. However, there was some good news: China's National Medical Products Administration gave the drug its first regulatory approval on Friday as a second-line treatment for patients with epidermal growth factor receptor (EFGR) mutated, advanced or metastatic NSCLC.
Was there any silver lining in the safety data presented by Akeso? Perhaps: Summit noted that the most common serious adverse events were related to chemotherapy rather than ivonescimab.
Not looking like $7 now after last news.
And another yesterday!
Is this finally the company’s time to shine?
- EP